Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.

Hong SH, Yoon IH, Kim YH, Yang SH, Park MJ, Nam HY, Kim B, Kim Y, Park CS, Park CG.

Immunobiology. 2010 Mar;215(3):182-93. doi: 10.1016/j.imbio.2009.01.010. Epub 2009 May 22.

PMID:
19464751
2.

Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.

Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E.

Blood. 2000 Mar 15;95(6):2024-30.

3.

IL-15 promotes the survival of naive and memory phenotype CD8+ T cells.

Berard M, Brandt K, Bulfone-Paus S, Tough DF.

J Immunol. 2003 May 15;170(10):5018-26. Erratum in: J Immunol. 2003 Aug 15;171(4):following 2169.

4.
5.

Evidence of a novel IL-2/15R beta-targeted cytokine involved in homeostatic proliferation of memory CD8+ T cells.

Kamimura D, Ueda N, Sawa Y, Hachida S, Atsumi T, Nakagawa T, Sawa S, Jin GH, Suzuki H, Ishihara K, Murakami M, Hirano T.

J Immunol. 2004 Nov 15;173(10):6041-9.

6.

Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide.

Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K.

Oncol Rep. 2006 Jul;16(1):141-6.

PMID:
16786137
7.

Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.

Terzieva V, Popova D, Kicheva M, Todorova Y, Markova R, Martinova F, Elenkov I, Yankova M.

Int Immunopharmacol. 2009 Jul;9(7-8):831-6. doi: 10.1016/j.intimp.2009.03.009. Epub 2009 Mar 18.

PMID:
19303058
8.

Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

Eberl G, Brawand P, MacDonald HR.

J Immunol. 2000 Oct 15;165(8):4305-11.

9.

CD4+ CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-beta-dependent manner in mice.

Wei HX, Chuang YH, Li B, Wei H, Sun R, Moritoki Y, Gershwin ME, Lian ZX, Tian Z.

J Immunol. 2008 Nov 15;181(10):7221-9.

10.

The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice.

Javeed A, Zhang B, Qu Y, Zhang A, Sun C, Zhang L, Liu J, Zeng C, Zhao Y.

Transpl Immunol. 2009 Mar;20(4):253-60. doi: 10.1016/j.trim.2008.12.001. Epub 2009 Jan 13.

PMID:
19146957
11.

OX40 controls functionally different T cell subsets and their resistance to depletion therapy.

Kroemer A, Xiao X, Vu MD, Gao W, Minamimura K, Chen M, Maki T, Li XC.

J Immunol. 2007 Oct 15;179(8):5584-91.

12.

Increased Toll-like receptor 4 expression on T cells may be a mechanism for enhanced T cell response late after burn injury.

Cairns B, Maile R, Barnes CM, Frelinger JA, Meyer AA.

J Trauma. 2006 Aug;61(2):293-8; discussion 298-9.

PMID:
16917441
13.

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, Zeng C, Zhao Y.

Transpl Immunol. 2007 Apr;17(3):153-61. Epub 2007 Jan 24.

PMID:
17331841
15.

Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.

Lee CH, Chiang YH, Chang SE, Chong CL, Cheng BM, Roffler SR.

Clin Cancer Res. 2009 Apr 15;15(8):2756-66. doi: 10.1158/1078-0432.CCR-08-2311. Epub 2009 Mar 24.

16.
17.

c-Myc acts downstream of IL-15 in the regulation of memory CD8 T-cell homeostasis.

Bianchi T, Gasser S, Trumpp A, MacDonald HR.

Blood. 2006 May 15;107(10):3992-9. Epub 2006 Jan 31.

18.

CD4+CD25+ and CD4+CD25- T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance.

Feunou P, Poulin L, Habran C, Le Moine A, Goldman M, Braun MY.

J Immunol. 2003 Oct 1;171(7):3475-84.

19.

Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.

Condomines M, Quittet P, Lu ZY, Nadal L, Latry P, Lopez E, Baudard M, Requirand G, Duperray C, Schved JF, Rossi JF, Tarte K, Klein B.

J Immunol. 2006 Jun 1;176(11):6631-9. Erratum in: J Immunol. 2006 Oct 15;177(8):5748.

20.

Supplemental Content

Support Center